Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Use of Mitomycin C to Lessen Unsightly Scarring Questioned

20.09.2004


Using an animal model, investigators find that Mitomycin C, a common chemotherapy agent, offers limited benefit in reducing keloid or hypertrophic scars.



The tendency for extreme scarring is one reason many African Americans avoid plastic surgery and other surgical incisions. Though surgeons continue to develop less invasive techniques that minimize scarring, other options are needed to help these individuals who are prone to developing keloid scars.

Keloid scars are caused by an overproduction of fibroblasts, the structure on which cells build tissue to heal a wound. The fibroblasts continue to multiply after the wound is filled in and become a raised scar that grows beyond the original wound or point of incision. Dark skinned individuals tend to form keloids more readily than lighter skinned individuals. Hypertrophic scars are more common and occur in all racial groups. They appear raised but stay within the confines of the initial wound or point of incision. Both types of scars can occur through skin injuries such as surgical incisions, traumatic wounds, vaccination sites, burns, chickenpox, acne, or even minor scratches.


Mitomycin C (MMC) is a common chemotherapy agent that inhibits cell growth. It is also known to decrease the proliferation of fibroblasts, an essential element in the development of scar tissue. If too many fibroblasts are produced, a keloid of hypertrophic scar is produced.

Researchers set out to determine if the use of Mitomycin C can reduce keloid or hypertrophic scarring. To do this, they used an animal model that most closely parallels normal wound healing in humans. Clinical observations were used to assess the effect of topical and intradermal MMC on wound healing while evaluating for the presence of the protein, TGF-B1, to determine how MMC works to decrease fibroblast proliferation and scarring.

The authors of the study, “The Effects of Intradermal and Topical Mitomycin C on Wound Healing,” are Glen T. Porter, MD, and Swarupa Gadre, MD, of the University of Texas Medical Branch in Galveston, TX, and Karen Calhoun, MD Chair of University of Missouri Medical School. Their findings are being presented at the American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

Methodology: Twenty-four adult male Sprague-Dawley rats (375-400g) were anesthetized and two incisions were placed on the back. Wound treatment was then administered according to randomization to one of the three study groups: injected MMC group, received intradermal injection with 1.0 ml of Mitomycin C (0.5mg/ml) into each wound; topical MMC group, received a four minute application of topical MMC (0.5mg/ml); saline group, received topical or intradermal saline in a similar manner. After treatment each wound was irrigated and closed with sterile staples. Two animals in each study arm were sacrificed at one and two weeks and one and six months after surgery. The wounds were then visually inspected and then a small sample was excised. Each wound was then serially sectioned. One section was sent for microscopic examination (blinded) with H&E staining and TGF-B1-specific immunohistochemical staining. Using a tensiometer, the remaining wound sections were tested to evaluate the force necessary to cause wound dehiscence (unblinded).

Results were evaluated using the SPSS software. Kruskal-Wallis and Mann-Whitney tests were used for statistical comparison. Study animals were treated in accordance to federal and state-mandated standards.

Results: Wound evaluation at the time of harvest showed an 88 percent (7/8) incidence of skin necrosis in the intradermal MMC group. Frank necrosis was noted in the wounds harvested at one and two weeks. Wounds harvested at one and six months showed corresponding areas of scarring consistent with areas of healing by secondary intention. No skin necrosis was noted in topical MMC and control animals. Wounds treated with topical MMC had poorer wound integrity compared with controls at one week (p<.001), two weeks (p<.001), one month (p<.001) and six months (p<.001). When compared to controls this represents a 3-4-fold decrease in wound strength at each time period. Intradermal MMC showed poorer wound integrity at two weeks (p<.001), one month (p<.001), and six months (p<.001) when compared with controls. Again, this represented at least a 3-fold decrease for the latter three time periods. There was a significant difference in wound strength when comparing topical and intradermal MMC only at the first week (p<.001) with injected wounds being weaker.

Blinded evaluation of H&E and immunohistochemical staining of wound sections showed no consistently identifiable difference between wounds in the three treatment groups. TGF-?1 was not consistently identified in any group.

Conclusions: The results of this study indicate that the application of MMC, whether topical or injected, will result in decreased wound strength which is still significantly different at six months after wounding. Intradermal injection appears to have no more affect on wound strength than topical, but carries an increased risk of skin necrosis. No consistently identifiable changes in histology or TGF-B1 expression was noted, which does not mean that TGF-B1 is not involved, only that the instrument of detection did not pick it up as the protein may not be present in quantities large enough to detect with immunohistochemical staining. This data suggests cautious use of MMC in clinical situations where wound breaking strength is critical. Intradermal MMC should be avoided as skin necrosis and scarring may result. Further study in humans is necessary to determine the effect of MMC on keloid and hypertrphic scars.

| newswise
Further information:
http://www.entnet.org

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>